NASDAQ:ADMS - Adamas Pharmaceuticals Stock Price, Forecast & News

Adamas Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMS."

Adamas Pharmaceuticals Inc (NASDAQ:ADMS) announced its quarterly earnings data on Thursday, November, 7th. The specialty pharmaceutical company reported ($0.99) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by $0.09. The specialty pharmaceutical company earned $13.93 million during the quarter, compared to analyst estimates of $14.36 million. Adamas Pharmaceuticals had a negative return on equity of 205.30% and a negative net margin of 215.09%. View Adamas Pharmaceuticals' Earnings History.

Adamas Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March 2nd 2020. View Earnings Estimates for Adamas Pharmaceuticals.

Adamas Pharmaceuticals issued an update on its FY 2019 Pre-Market earnings guidance on Wednesday, January, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $54.6-54.6 million, compared to the consensus revenue estimate of $53.65 million.

10 equities research analysts have issued 1 year price targets for Adamas Pharmaceuticals' stock. Their forecasts range from $5.00 to $55.00. On average, they anticipate Adamas Pharmaceuticals' stock price to reach $15.67 in the next twelve months. This suggests a possible upside of 160.7% from the stock's current price. View Analyst Price Targets for Adamas Pharmaceuticals.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adamas Pharmaceuticals in the last year. There are currently 2 sell ratings, 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Adamas Pharmaceuticals.

News articles about ADMS stock have been trending extremely negative on Thursday, InfoTrie reports. The research group ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Adamas Pharmaceuticals earned a coverage optimism score of -5.0 on InfoTrie's scale. They also gave press coverage about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Adamas Pharmaceuticals.

Adamas Pharmaceuticals saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 2,380,000 shares, an increase of 28.6% from the December 15th total of 1,850,000 shares. Based on an average trading volume of 658,300 shares, the short-interest ratio is currently 3.6 days. Approximately 10.7% of the company's stock are sold short. View Adamas Pharmaceuticals' Current Options Chain.

Some companies that are related to Adamas Pharmaceuticals include Akero Therapeutics (AKRO), Axovant Sciences (AXON), Vectura Group (VEGPF), AC Immune (ACIU), Urogen Pharma (URGN), Morphic (MORF), Kadmon (KDMN), Crinetics Pharmaceuticals (CRNX), Kura Oncology (KURA), MacroGenics (MGNX), Prothena (PRTA), Magenta Therapeutics (MGTA), Neoleukin Therapeutics (NLTX), Clovis Oncology (CLVS) and Viking Therapeutics (VKTX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Adamas Pharmaceuticals investors own include Rite Aid (RAD), Sangamo Therapeutics (SGMO), Abeona Therapeutics (ABEO), Exelixis (EXEL), ACADIA Pharmaceuticals (ACAD), Ardelyx (ARDX), Cara Therapeutics (CARA), Century Aluminum (CENX), Omeros (OMER) and TG Therapeutics (TGTX).

Shares of ADMS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ADMS stock can currently be purchased for approximately $6.01.

Adamas Pharmaceuticals has a market capitalization of $167.43 million and generates $34.05 million in revenue each year. The specialty pharmaceutical company earns $-131,000,000.00 in net income (profit) each year or ($4.87) on an earnings per share basis. Adamas Pharmaceuticals employs 159 workers across the globe.View Additional Information About Adamas Pharmaceuticals.

The official website for Adamas Pharmaceuticals is http://www.adamaspharma.com/.

Adamas Pharmaceuticals' mailing address is 1900 POWELL ST. SUITE 1000, EMERYVILLE CA, 94608. The specialty pharmaceutical company can be reached via phone at 510-450-3500 or via email at [email protected]